In AD post-mortem brains as well as in APP1 transgenic mouse models, VDAC1 was found to be over expressed in patients, and the possibility of decreasing it by using low doses of STX can be a fascinating therapeutic option [33]. This evidence concerns the gene VDAC1 and Alzheimer disease.